abstract -Purpose: Pregnancy management poses an extra challenge to physicians and their multiple sclerosis (MS) patients. There are few papers reporting databases on the subject. Method: Brazilian database from nine MS clinical and research units, with complete data on 47 pregnant women (49 pregnancies). Results: Despite relatively high exposure to MS medications, no birth defects were reported. Low birth weight and prematurity were similar to those for developing countries. Three complications may have been associated with these medications, while three others were considered to be of purely obstetric nature. Conclusion: Our results confirm previous findings on lower relapse rate during pregnancy and add to the present literature informing on data related to drug exposure.
, estrogens 4 and estriol 5 and expression of chemokine receptors 6 . During pregnancy, both the inherent reduction in relapses and the uncertainty about the safety of drugs used for MS, encourage physicians not to prescribe any medications. however, many women using MS drugs become pregnant while taking these medications, even if they stop any treatment as soon as they realize they are pregnant. Some physicians may, even when aware of the risks, consider it necessary to continue with some medications for their patients, and follow the recommendations of the Food and Drug Administration (FDA).
The FDA classification for MS immunomodulatory and immunosuppressive drugs specifies that there are no safe class A drugs. class B drugs include immunoglobulin and glatiramer acetate. class c includes beta-interferons, mitoxantrone and corticosteroids. Drugs with evidence of fetal risk, where the risk and benefit should be carefully assessed, include azathioprine and cyclophosphamide. Methotrexate is considered to be very high risk (class X) and should not be used for potentially fertile women.
The relative rarity of data on pregnancy and MS has encouraged our study 7 .
Method
Over a period of ten months in 2008, MS researchers in Brazil were invited to send data from the last five years on their cases of pregnancy in MS patients. Those who showed interest in this study received, by e-mail, a specific excel file. Two of the re- searchers (AF, yDF) received the returned files and (AF) analyzed the data. The present paper was written by one of the researchers (yDF) and its contents were approved by all participants prior to submission. This work was not carried out at a single institution and it was undertaken on the authors' own initiative, working without any financial support. Authorization from ethics committees and patients' consent were individually obtained by the authors, in accordance with the regulations of their workplaces. The excel file included each patient's demographic data, history and characteristics of MS, data on clinical and neurological conditions, time of each pregnancy, medications in use at any gestational stage, number and timing of relapses, birth outcome and breastfeeding details.
The t-test was used to calculate continuous data and the chi-square test, for categorical data. correlations were assessed using the ANOvA, Pearson and Spearman tests. results were considered to be significant when p<0.05. SPSS version 11.5 was used for all the analyses. reSultS complete data from 47 women (49 pregnancies) were received and analyzed. A summary of the demographic and gestational data is presented in Table 1 . regular treatment at the time of pregnancy diagnosis was: interferonbeta (17 cases), glatiramer acetate (15 cases), methotrexate (1 case) and corticosteroids (1 case), while 15 patients were not receiving any regular medication. Glatiramer acetate was continuously administered during pregnancy in 12 patients, in accordance with their physicians' decision and discretion. Although decreased, postpartum relapse rate in these cases were not significantly reduced in patients who used drugs throughout pregnancy (p=0.41).
There were no cases of fetal malformation. Obstetric complications consisted of one neonatal death (hospital infection), one abortion (polycystic ovaries and obesity) and one shoulder dystocia (baby >3,500 g).
The following complications might have been drug-related. One case of abortion was temporally related to a relapse and the use of immunoglobulin. It cannot be ruled out that one case of hemorrhage and one case of delayed intrauterine growth might have been related to MS or its treatment (corticosteroids and interferon-beta 1a 22 mcg three times a week, at start of pregnancy, respectively).
One case of neonatal jaundice was reported in a patient without drug exposure. There was one case of twins, born without complications, despite one sibling's low weight. Low birth weight or prematurity rates were similar to those for developing countries (7 cases, 14.8%). Both low birth weight and prematurity were observed in three of these babies. These cases could not be correlated to any drugs, eDSS or MS duration. The only patient using methotrexate, who became pregnant despite counseling and the use of birth control pills, did not present any complication during or after pregnancy, and her normal child is now two years old.
A summary of data on the potential effect of drugs is presented in Table 2 . diScuSSion This is the first Brazilian collaborative study on pregnancy and MS. The present work reports on one of the largest series of cases (49 pregnancies) recorded in proper databases in the world [7] [8] [9] [10] [11] [12] . Only pregnancy cases from canada (n=16) 7 , Sweden 8 (n=69), Spain 9 (n=88), Finland 10 (n=42), Italy 11 (n=38) and Germany 12 (n=88) have been previously reported in the literature with a similar methodology.
Our results showed no correlation among parameters in early pregnancy (different drugs, eDSS and time of disease) and poor gestational outcome (low birth-weight, prematurity, birth defects and drug-related complications). The lower relapse rate during pregnancy was in accordance with expected results 1 . No significant increase in relapse rate was observed in the postpartum period. Our patients were of relatively young age, with low eDSS at the beginning of pregnancy, nearly half of them in their first pregnancy, and only a small number of relapses in the year preceding pregnancy. These findings corroborate the idea, already noted by others 13, 14 , that perhaps women in better clinical condition have increased propensity to maternity, at the same time that those using more aggressive cytotoxic treatments may present impaired fertility 15 . The use of FDA class B drugs during pregnancy did not significantly alter the postpartum relapse rate. This finding further corroborates the concept that there is no indication for continuous use of medication during gestation, and that medical prescription should be used only in very particular cases. however, it must be considered that only the most aggressive forms of MS were treated during pregnancy in Brazil, and the similar relapse rate in those who used immunomodulators must be further assessed. Data collection in Brazil continues, assessing MS and pregnancy parameters, as well as drug exposure. Physicians who are interested in joining the database should send an e-mail to lampreg@yahoo.com indicating their willingness to participate in the study.
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